Literature DB >> 1979030

Mechanisms of impaired growth hormone secretion in genetically obese Zucker rats: roles of growth hormone-releasing factor and somatostatin.

G S Tannenbaum1, M Lapointe, W Gurd, J A Finkelstein.   

Abstract

GH secretion is markedly blunted in obesity; however, the mechanism(s) mediating this response remains to be elucidated. In the present study we examined the involvement of the two hypothalamic GH-regulatory hormones, GH-releasing factor (GRF) and somatostatin (SRIF), using the genetically obese male Zucker rat. Spontaneous GH, insulin, and glucose secretory profiles obtained from free moving, chronically cannulated rats revealed a marked suppression in amplitude and duration of GH pulses in obese Zucker rats compared to their lean littermates (mean 6-h plasma GH level, 3.9 +/- 0.4 vs. 21.5 +/- 3.8 ng/ml; P less than 0.001). Obese rats also exhibited significant hyperinsulinemia in the presence of normoglycemia. The plasma GH response to an iv bolus of 1 microgram rat GRF-(1-29)NH2, administered during peak and trough periods of the GH rhythm, was significantly attenuated in obese rats at peak (137.4 +/- 26.1 vs. 266.9 +/- 40.7 ng/ml; P less than 0.02), although not at trough, times. Passive immunization of obese rats with a specific antiserum to SRIF failed to restore the amplitude of GH pulses to normal values; the mean 6-h plasma GH level of obese rats given SRIF antiserum was not significantly different from that of obese rats administered normal sheep serum. Both pituitary wet weight and pituitary GH content and concentration were reduced in the obese group. Measurement of hypothalamic GRF immunoreactivity revealed a significant (P less than 0.05) reduction in the mediobasal hypothalamic GRF content in obese rats (503.2 +/- 60.1 pg/fragment) compared to that in lean controls (678.1 +/- 50.2 pg/fragment), although no significant difference was observed in hypothalamic SRIF concentration. Peripheral SRIF immunoreactive levels were significantly (P less than 0.01) elevated in both the pancreas and stomach of obese rats. These results demonstrate that the genetically obese Zucker rat exhibits 1) marked impairment in both spontaneous and GRF-induced GH release, which cannot be reversed by SRIF immunoneutralization, 2) significant reduction in pituitary GH concentration, 3) depressed hypothalamic GRF content, and 4) elevated gastric and pancreatic, but not hypothalamic, SRIF levels. The findings suggest that the defect in pituitary GH secretion observed in the genetically obese Zucker rat is due, at least partially, to insufficient stimulation by hypothalamic GRF, and that SRIF does not play a significant role.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1979030     DOI: 10.1210/endo-127-6-3087

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  12 in total

1.  Feedback modeling of non-esterified fatty acids in obese Zucker rats after nicotinic acid infusions.

Authors:  Christine Ahlström; Tobias Kroon; Lambertus A Peletier; Johan Gabrielsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-10-10       Impact factor: 2.745

2.  GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology.

Authors:  A Corrias; J Bellone; L Beccaria; L Bosio; G Trifirò; C Livieri; L Ragusa; A Salvatoni; M Andreo; P Ciampalini; G Tonini; A Crinò
Journal:  J Endocrinol Invest       Date:  2000-02       Impact factor: 4.256

3.  Assessment of GH/IGF-I axis in obesity by evaluation of IGF-I levels and the GH response to GHRH+arginine test.

Authors:  M Maccario; C Gauna; M Procopio; L Di Vito; R Rossetto; S E Oleandri; S Grottoli; C Ganzaroli; G Aimaretti; E Ghigo
Journal:  J Endocrinol Invest       Date:  1999-06       Impact factor: 4.256

4.  Effect of bromocriptine on insulin, growth hormone and prolactin responses to arginine in obesity.

Authors:  M Maccario; S Grottoli; M Procopio; S E Oleandri; A Barberis; E Ciccarelli; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  1996-04       Impact factor: 4.256

5.  The activity of GH/IGF-I axis in anorexia nervosa and in obesity: a comparison with normal subjects and patients with hypopituitarism or critical illness.

Authors:  L Gianotti; F Broglio; J Ramunni; F Lanfranco; C Gauna; A Benso; M Zanello; E Arvat; E Ghigo
Journal:  Eat Weight Disord       Date:  1998-06       Impact factor: 4.652

6.  Effects of alprazolam, a benzodiazepine, on the ACTH-, GH- and PRL-releasing activity of hexarelin, a synthetic peptidyl GH secretagogue (GHS), in patients with simple obesity and in patients with Cushing's disease.

Authors:  S Grottoli; E Arvat; C Gauna; B Maccagno; J Ramunni; R Giordano; M Maccario; R Deghenghi; E Ghigo
Journal:  Pituitary       Date:  1999-11       Impact factor: 4.107

Review 7.  Hypothalamic and hypophyseal regulation of growth hormone secretion.

Authors:  M T Bluet-Pajot; J Epelbaum; D Gourdji; C Hammond; C Kordon
Journal:  Cell Mol Neurobiol       Date:  1998-02       Impact factor: 5.046

8.  Impaired hypothalamic regulation of endocrine function and delayed counterregulatory response to hypoglycemia in Magel2-null mice.

Authors:  Alysa A Tennese; Rachel Wevrick
Journal:  Endocrinology       Date:  2011-01-19       Impact factor: 4.736

9.  Glucagon administration elicits blunted GH but exaggerated ACTH response in obesity.

Authors:  F Tassone; S Grottoli; R Rossetto; B Maccagno; C Gauna; R Giordano; E Ghigo; M Maccario
Journal:  J Endocrinol Invest       Date:  2002-06       Impact factor: 4.256

10.  Body fat distribution, blood pressure and blood glucose in Egyptian obese women undergoing a weight control program.

Authors:  S M el-Shebini; S T Tapozada; L M Hanna
Journal:  Z Ernahrungswiss       Date:  1993-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.